Literature DB >> 7684518

Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan.

W C Su1, T Y Chen, R H Kao, C J Tsao.   

Abstract

Twenty-five patients with metastatic and/or recurrent nasopharyngeal carcinoma were treated with cisplatin 20 mg/m2/day on days 1-5 i.v. with hydration; 5-fluorouracil (5-FU) 1,000 mg/m2/day by continuous infusion (CI); and bleomycin 15 mg/m2 on day 1 also by CI. These cycles were repeated every 4 weeks. Twenty-three (92%) had distant metastases. Bone was the most frequently involved site (72%), followed by lungs (44%) and liver (40%). More than half the patients (14/25) presented with at least 3 organ sites involved or had local T3/T4 or N3 lesions with a distant metastasis. The median time from relapse to start of chemotherapy was 7.5 months. We observed 1 (4%) complete response (CR), and 9 (36%) partial responses (PR). The objective response rate (CR + PR) was 40%. Hematologic toxicities were frequently encountered. Twenty (80%) patients experienced leukopenia during the treatment courses and 9 (36%) had severe (grade 3 or 4) leukopenia. Eight patients had grade 3 or 4 infections. Two of them died of sepsis and 1 succumbed to uncontrolled pneumonia. The objective response rate was inferior to other series. Possible explanation included longer delay before initiation of definitive treatment, larger tumor burdens, higher severe hematologic toxicity and lower dosage of bleomycin. The results suggested metastatic and/or recurrent nasopharyngeal carcinoma is chemosensitive, however, for patients with large tumor burdens, more intensive chemotherapy regimens with support of hematopoietic growth factors may be required to achieve a better control.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684518     DOI: 10.1159/000227179

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.

Authors:  Ying Jin; Yan-Xia Shi; Xiu-Yu Cai; Xi-Ya Xia; Yu-Chen Cai; Ye Cao; Wei-Dong Zhang; Wei-Han Hu; Wen-Qi Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-10       Impact factor: 4.553

2.  An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.

Authors:  Sik-Kwan Chan; Brian O'Sullivan; Shao Hui Huang; Tin-Ching Chau; Ka-On Lam; Sum-Yin Chan; Chi-Chung Tong; Varut Vardhanabhuti; Dora Lai-Wan Kwong; Chor-Yi Ng; To-Wai Leung; Mai-Yee Luk; Anne Wing-Mui Lee; Horace Cheuk-Wai Choi; Victor Ho-Fun Lee
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

3.  Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.

Authors:  R L Hong; T S Sheen; J Y Ko; M M Hsu; C C Wang; L L Ting
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 4.  Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.

Authors:  A Prawira; S F Oosting; T W Chen; K A Delos Santos; R Saluja; L Wang; L L Siu; K K W Chan; A R Hansen
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

5.  Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.

Authors:  Victor H F Lee; Dora L W Kwong; Ka-On Lam; Yu-Ching Lai; Yun Li; Chi-Chung Tong; Patty P Y Ho; Wing-Lok Chan; Lai-San Wong; Dennis K C Leung; Sum-Yin Chan; Fong-Ting Chan; To-Wai Leung; Anne W M Lee
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Asiatic Acid, Extracted from Centella asiatica and Induces Apoptosis Pathway through the Phosphorylation p38 Mitogen-Activated Protein Kinase in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells.

Authors:  Yen-Tze Liu; Yi-Ching Chuang; Yu-Sheng Lo; Chia-Chieh Lin; Yi-Ting Hsi; Ming-Ju Hsieh; Mu-Kuan Chen
Journal:  Biomolecules       Date:  2020-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.